Trials / Withdrawn
WithdrawnNCT02483936
Efficacy and Safety of Olmesartan Associated With Chlorthalidone Versus Benicar HCT® in Essential Hypertension Control
Efficacy and Safety Evaluation of the New Association on Fixed Dose of Olmesartan Medoxomil + Chlorthalidone (40mg + 12.5mg and 40mg + 25mg) Compared With BENICAR HCT® in Hypertension Control
- Status
- Withdrawn
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- EMS · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the non-inferiority clinical efficacy of two different drug associations in the essential hypertension control.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Olmesartan medoxomil 40mg + chlorthalidone 12,5mg | 1 tablet a day |
| DRUG | Olmesartan medoxomil 40mg + chlorthalidone 25mg | 1 tablet a day |
| DRUG | Olmesartan 40mg + Hydrochlorothiazide 12,5mg | 1 tablet a day |
| DRUG | Olmesartan 40mg + Hydrochlorothiazide 25mg | 1 tablet a day |
Timeline
- Primary completion
- 2025-06-01
- First posted
- 2015-06-29
- Last updated
- 2025-12-08
Source: ClinicalTrials.gov record NCT02483936. Inclusion in this directory is not an endorsement.